These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 22364675)
1. Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. Koranek AM; Smith TL; Mican LM; Rascati KL Schizophr Res; 2012 May; 137(1-3):137-40. PubMed ID: 22364675 [TBL] [Abstract][Full Text] [Related]
2. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. Berkowitz RL; Patel U; Ni Q; Parks JJ; Docherty JP J Clin Psychiatry; 2012 Apr; 73(4):498-503. PubMed ID: 22226332 [TBL] [Abstract][Full Text] [Related]
3. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. Bret P; Bret MC; Queuille E Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK; Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466 [TBL] [Abstract][Full Text] [Related]
5. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. Naber D; Lambert M CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194 [TBL] [Abstract][Full Text] [Related]
6. Impact of the CATIE trial on antipsychotic prescribing. Citrome L Schizophr Res; 2012 Jul; 138(2-3):295. PubMed ID: 22503639 [No Abstract] [Full Text] [Related]
7. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone]. Bret P; Bonnet F; Bret MC; Jaffré A Encephale; 2002; 28(4):329-42. PubMed ID: 12232542 [TBL] [Abstract][Full Text] [Related]
8. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Resnick SG; Rosenheck RA; Canive JM; De Souza C; Stroup TS; McEvoy J; Davis S; Keefe RS; Swartz M; Lieberman J J Behav Health Serv Res; 2008 Apr; 35(2):215-25. PubMed ID: 18246429 [TBL] [Abstract][Full Text] [Related]
10. [Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study]. Gutiérrez-Suela F Farm Hosp; 2008; 32(2):83-90. PubMed ID: 18783707 [TBL] [Abstract][Full Text] [Related]
11. Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. Rosenheck R; Lin H J Nerv Ment Dis; 2014 Jan; 202(1):18-24. PubMed ID: 24375207 [TBL] [Abstract][Full Text] [Related]
12. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ; Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746 [TBL] [Abstract][Full Text] [Related]
13. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Addington DE; Mohamed S; Rosenheck RA; Davis SM; Stroup TS; McEvoy JP; Swartz MS; Lieberman JA J Clin Psychiatry; 2011 Jan; 72(1):75-80. PubMed ID: 20868641 [TBL] [Abstract][Full Text] [Related]
14. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Foussias G; Remington G Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J; Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158 [TBL] [Abstract][Full Text] [Related]
16. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033 [TBL] [Abstract][Full Text] [Related]
17. Change of psychotropic drug prescription for schizophrenia in a psychiatric institution in Beijing, China between 1999 and 2008. An FR; Xiang YT; Wang CY; Zhang GP; Chiu HF; Chan SS; Lee EH; Ungvari GS Int J Clin Pharmacol Ther; 2010 Apr; 48(4):270-4. PubMed ID: 20353748 [TBL] [Abstract][Full Text] [Related]
18. The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland. Jaracz J; Tetera-Rudnicka E; Kujath D; Raczyńska A; Stoszek S; Czernaś W; Wierzbiński P; Moniakowski A; Jaracz K; Rybakowski J Pharmacol Rep; 2014 Aug; 66(4):613-7. PubMed ID: 24948062 [TBL] [Abstract][Full Text] [Related]
20. Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium. Cleymans S; Morrens M; Bervoets C J Med Ethics; 2017 Jun; 43(6):359-363. PubMed ID: 27895084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]